Table 1. Characteristics for COPACATIC and LEUVEN at baseline and after three-year follow-up for COPACETIC.
| COPACETIC | LEUVEN | ||
| Baseline (n = 1,226) | Follow-up (n = 1,226) | (n = 883) | |
| Demographics | |||
| Age, mean (SD), yr | 59.7 (5.3) | 62.7 (5.4) | 63.9 (8.0) |
| Male sex, no. (%) | 1,226 (100) | 1,226 (100) | 656 (74.0) |
| Height, mean (SD), cm | 177.5 (6.5) | 178.1 (6.3) | 169.6 (8.9) |
| Smoking | |||
| Pack-year history, mean (SD), yr | 40.7 (17.4) | N/A | 47.4 (24.8) |
| Current smokers, no. (%) | 753 (61.4) | N/A | 367 (41.3) |
| Smoked years, mean (SD), yr | 39.6 (8.87) | N/A | 41.7 (9.0) |
| Years quit smokers, median (25th–75th percentiles) | 8.1 (3.0–9.0) | N/A | 1.0 (0.0–8.0) |
| Pulmonary function tests, mean (SD) | |||
| FEV1, L | 3.33 (0.73) | 3.14 (0.72) | 1.92 (1.08) |
| FEV1, % predicted | 96.5 (18.4) | 93.7 (18.8) | 65.4 (32.7) |
| FVC, L | 4.70 (0.79) | 4.61 (0.81) | 3.36 (1.13) |
| FVC, % predicted | 107.1 (14.6) | 106.7 (15.3) | 91.9 (24.3) |
| MEF50, L/s | 3.08 (1.45) | 2.76 (1.38) | 1.52 (1.50) |
| FEV1/FVC ratio | 0.71 (0.10) | 0.68 (0.10) | 0.54 (0.18) |
| COPD severity, no. (%) | |||
| No Obstruction | 682 (55.6) | 557 (45.4) | 230 (26.0) |
| GOLD class I | 357 (29.1) | 430 (35.1) | 123 (13.9) |
| GOLD class II | 162 (13.2) | 210 (17.1) | 183 (20.7) |
| GOLD class III | 24 (2.0) | 23 (1.9) | 188 (21.2) |
| GOLD class IV | 0 | 5 (0.4) | 159 (18.0) |
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease; GOLD: global initiative for chronic obstructive lung disease; N/A: non-applicable. Percentages are column percentages. Of the LEUVEN participants, 653 subjects were diagnosed with COPD (FEV1/FVC<0.70).